Has been in a consistent uptrend since July 2021. Points raised below.
- broke initial resistance level at ~6750
- tested twice the next resistance level at 7200
- on weekly chart, 50day MA about to break above 200day MA
One of the best looking charts on the JSE. I bought in yesterday (20220414) at 7263. Results should be released soon.
- broke initial resistance level at ~6750
- tested twice the next resistance level at 7200
- on weekly chart, 50day MA about to break above 200day MA
One of the best looking charts on the JSE. I bought in yesterday (20220414) at 7263. Results should be released soon.
Trade active:
Results released this morning (snippet below from SENS).
Highlights
- Strong financial performance driven by increased client activity
- Group revenue growth around 8% in the year and improved Group EBITDA margin
at around 16.0% (FY21: 14.2%)
- Recovery in profitability and strong cash conversion leading to significant
reduction in leverage ratio
- Expect positive momentum in client activity to drive revenue growth and margins
in the coming year
Highlights
- Strong financial performance driven by increased client activity
- Group revenue growth around 8% in the year and improved Group EBITDA margin
at around 16.0% (FY21: 14.2%)
- Recovery in profitability and strong cash conversion leading to significant
reduction in leverage ratio
- Expect positive momentum in client activity to drive revenue growth and margins
in the coming year
Trade active:
*Remgro says Mediclinic's board of directors rejects Remgro's takeover offer of 460 pence
Trade closed: target reached